IL2 and non-small cell lung carcinoma: The inclusion of IL-2 in this treatment regimen is based on the reason of that an activated immune system can significantly augment the efficacy of direct cytotoxic effects on tumor cells, offering a dual approach to combating advanced NSCLC 23-24.